Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 99   

Articles published

LGND 85.37 -2.89 (-3.27%)
price chart
Hanseatic Management Services Inc. Invests $839000 in Ligand Pharmaceuticals ...
Ligand Pharmaceuticals logo Hanseatic Management Services Inc. bought a new position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
Ligand Pharmaceuticals Inc. (LGND) Issues Earnings Results  Intercooler Financial
Ligand Pharmaceuticals Inc. (LGND) Releases Earnings Results, Beats ...  The Vista Voice
Anticipated EPS Rise for Ligand Pharmaceuticals Inc. (LGND)
Analysts await Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to reports earnings on February, 8. They expect $0.51 earnings per share, up 6.25 % or $0.03 from last year's $0.48 per share.
Ligand Pharmaceuticals (LGND): Q4 Earnings Preview
The revised guidance mainly reflected the delay in the timing of receipt of the $6 million milestone payment due from Spectrum Pharmaceuticals, Inc. (SPPI - Analyst Report), upon FDA approval of Evomela. Spectrum received a complete response letter ...
Ligand Pharmaceuticals Inc. (LGND) to Release Earnings on Wednesday  Daily Political
Woodstock Sells 745 Shares of Ligand Pharmaceuticals Inc. (LGND)
Ligand Pharmaceuticals logo Woodstock cut its stake in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 1.1% during the fourth quarter, according to its most recent filing with the SEC.
Ligand Pharmaceuticals Inc. (LGND) Rating Reiterated by Roth Capital  Zolmax
Ligand Pharmaceuticals Inc. (LGND) Earns "Buy" Rating from Roth Capital
Ligand Pharmaceuticals Inc. logo Roth Capital reissued their buy rating on shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) in a research note issued to investors on Wednesday morning, Market Beat reports.
Woodstock Reduces Stake in Ligand Pharmaceuticals Inc. (LGND)  Intercooler Financial
Investor's Watch: Ligand Pharmaceuticals Inc.  iStreetWire
Insider Selling: Ligand Pharmaceuticals Inc. (LGND) Director Sells $158170.04 ...
Ligand Pharmaceuticals logo Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director John W. Kozarich sold 1,666 shares of the firm's stock in a transaction on Wednesday, January 20th.
Roth Capital Reiterates Buy Rating for Ligand Pharmaceuticals Inc. (LGND)  Corvus Business Newswire
Ligand Pharmaceuticals Incorporated Witness Inflow of Net $0.35M  Analyst Rating Reports
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Receives Consensus Rating of "Buy ...
Ligand Pharmaceuticals logo Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the firm, Marketbeat reports.
Wall Street Puts $125 Price Target on Ligand Pharmaceuticals Incorporated ...  Markets Daily
Ligand Pharmaceuticals Inc. (LGND) Director John W. Kozarich Sells 1666 Shares ...
Ligand Pharmaceuticals logo Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director John W. Kozarich sold 1,666 shares of the business's stock in a transaction on Wednesday, January 20th.
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Given Average Recommendation of ...  EMQ
Technical and Fundamental Brief on Ligand Pharmaceuticals Inc (NASDAQ:LGND)  Street Report
Ligand Pharmaceuticals Inc. (LGND) Stake Boosted by AMI Asset Management Corp
Ligand Pharmaceuticals logo AMI Asset Management Corp boosted its position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 7.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
Company Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Drops by ...  Market Briefing
Analyst Stock Update: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)  Equities Focus
Ligand Pharmaceuticals Inc. (LGND) Set to Announce Quarterly Earnings on Wednesday
Ligand Pharmaceuticals logo Ligand Pharmaceuticals Inc. (NASDAQ:LGND) is set to announce its Q415 earnings results on Wednesday, February 10th.
Ligand Pharmaceuticals Inc. (LGND) Profit Expected to Increase  WallStreet.org
Earnings in Focus: Ligand Pharmaceuticals Incorporated (LGND)  CWRU Observer